Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

News
Article
Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.
Penpulimab (formerly AK105), an anti–PD-1 monoclonal antibody, has received approval from the National
Read more...